血浆ATⅡ、NPY、IGF-1和hs-CRP水平测定在评估冠心病患者严重程度中的应用价值

The application value of plsama ATⅡ, NPY, IGF-1 and hs-CRP levels in evaluation of coronary heart disease severity

目的：探讨血浆血管紧张素Ⅱ（ATⅡ）、神经肽Y（NPY）、胰岛素样生长因子1（IGF-1）和高敏C反应蛋白（hs-CRP）水平测定在评估冠心病患者严重程度中的应用价值。方法采用放射免疫分析、酶免疫分析和高敏酶免疫分析法分别测定157例冠心病患者[包括51例稳定型心绞痛（SA）患者、45例不稳定型心绞痛（USA）患者和61例急性心肌梗死（AMI）患者]的血浆ATⅡ、NPY、IGF-1和hs-CRP水平，并与60名正常对照者进行对比分析。结果157例CHD患者血浆ATⅡ水平与60名正常对照者相比，差异有统计学意义（tSA ATⅡ=2．257，P＜0．05；tUSA ATⅡ=3．018，P＜0．01；tAMI ATⅡ=4．143，P＜0．001）；血浆NPY水平较正常对照者增高（tSA NPY=1．413，P＞0．05；tUSA NPY=2．148，P＜0．05；tAMI NPY=3．068，P＜0．01），但SA患者与正常对照者之间的差异无统计学意义；血浆IGF-1水平与正常对照者相比，差异有统计学意义（tSA IGF-1=2．121，P＜0．05；tUSA IGF-1=2．937，P＜0．01；tAMIIGF-1=4．217，P＜0．001）；血浆hs-CRP水平与正常对照者相比，差异有统计学意义（tSAhs-CRP=2．095，P＜0．05；tUSA hs-CRP=2．867，P＜0．01；tAMI hs-CRP=4．349，P＜0．001）。血浆ATⅡ、NPY、IGF-1和hs-CRP水平随着SA、USA和AMI患者的严重程度而增高。结论血浆ATⅡ、NPY、IGF-1和hs-CRP水平是判断冠心病患者严重程度的有价值指标，亦可以用于治疗后的随访。

Objective To explore the application value of angiotensinⅡ （ATⅡ）, neuropeptide Y（NPY）, insulin-like growth factor 1（IGF-1） and high sensitive C-reaction protein（hs-CRP） levels in e-valuation of the severity of coronary heart disease （CHD）. Methods The plasma ATⅡ, NPY, IGF-1 and hs-CRP levels in 157 patients with CHD [ including 51 cases with stable angina （ SA ） , 45 cases with unstable angina （USA） and 61 cases with acute myocardial infraction （AMI）] were measured by radioim-munoassay, enzyme immunoassay and high sensitive enzyme immunoassay and were compared with 60 health controls. Results The plasma ATⅡlevel in 157 patients with CHD was significantly higher than those in 60 controls（tSA ATⅡ=2.257, P〈0.05; tUSAATⅡ=3.018, P〈0.01; tAMIATⅡ=4.143, P〈0.001）. The plasma NPY level in 157 patients with CHD was higher than those in 60 controls （tSANPY=1.413, P＆gt;0.05;tUSANPY=2.148, P〈0.05; tAMINPY=3.068, P〈0.01）, but there were no significant difference between SA pa-tients and the 60 conrols. The plasma IGF-1 level in 157 patients with CHD was significantly higher than those in 60 controls （tSA IGF-1=2.121, P〈0.05; tUSA IGF-1=2.937, P〈0.01; tAMI IGF-1=4.217, P〈0.001）. The plasma hs-CRP level in 157 patients with CHD was significantly higher than those in 60 controls （tSA hs-CRP=2.095, P〈0.05; tUSA hs-CRP=2.867, P〈0.01; tAMI hs-CRP=4.349, P〈0.001）. The four plasma biomarkers were increased with severity of CHD. Conclusion The plasma ATⅡ, NPY, IGF-1 and hs-CRP levels were＆amp;nbsp;valuable indexes for judging the severity of patients with CHD, and could be used for follow-up.